New drug combo takes on advanced cancers in first human trial
NCT ID NCT07376707
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial is testing a new drug called TGI-5, given alone or with the immunotherapy nivolumab, in people with advanced solid tumors such as colorectal, liver, lung, and skin cancers. The study aims to find safe doses and check for side effects in about 194 participants. It is the first time TGI-5 is being tested in humans, so the main goal is safety, not yet proving it works against cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- TGI-5 (a drug) alone or combined with nivolumab (an immunotherapy)
- What this could lead to
- If this early trial shows promise, it could point toward a new treatment option for people with advanced solid tumors like colorectal, liver, lung, or skin cancer.
- What could go wrong
- This is a very early Phase 1 study with only 194 participants, focused mainly on safety and dosing. The drug may not shrink tumors or could cause side effects. Success is far from guaranteed.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fudan University Shanghai Cancer Center
RECRUITINGShanghai, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.